#1 Clinical Trials Search in Europe

Darbepoetin Alfa

Darbepoetin alfa, also known by the brand name Aranesp, is a medication being studied in clinical trials for treating anemia associated with various medical conditions. These trials are investigating its effectiveness and safety in patients with chronic kidney disease, cancer, myelodysplastic syndromes, and other conditions that can cause anemia. The studies are looking at different dosing regimens and comparing darbepoetin alfa to other anemia treatments to determine the optimal use of this drug.

Table of Contents

What is Darbepoetin Alfa?

Darbepoetin alfa is a medication used to treat anemia, a condition where the body doesn’t have enough healthy red blood cells to carry oxygen effectively. It’s known by the brand names Aranesp® and BCD-066[1][2]. This drug is a man-made version of a protein that helps your body produce red blood cells, similar to the natural hormone erythropoietin that your kidneys normally make[3].

Conditions Treated with Darbepoetin Alfa

Darbepoetin alfa is used to treat anemia in several conditions:

  • Chronic Kidney Disease (CKD): For patients with kidney problems, including those on dialysis[4][5]
  • Cancer: For patients receiving chemotherapy, especially those with non-myeloid malignancies (cancers not affecting bone marrow)[6]
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[7]
  • Erythroblastosis Fetalis: A condition in newborns where there’s a mismatch between the mother’s and baby’s blood types, leading to the destruction of the baby’s red blood cells[8]

How Darbepoetin Alfa Works

Darbepoetin alfa works by stimulating your bone marrow to produce more red blood cells. This helps increase the hemoglobin levels in your blood. Hemoglobin is the protein in red blood cells that carries oxygen throughout your body. By increasing your hemoglobin levels, darbepoetin alfa helps reduce the symptoms of anemia, such as fatigue and weakness[3][6].

How Darbepoetin Alfa is Administered

Darbepoetin alfa is typically given as an injection under the skin (subcutaneously) or into a vein (intravenously). The dosage and frequency can vary depending on your condition and how you respond to the treatment. Some common dosing schedules include:

  • Once every week
  • Once every two weeks
  • Once every three weeks
  • Once monthly (in some cases for dialysis patients)[4][5][6]

Your doctor will determine the best dosing schedule for you based on your specific needs and condition.

Effectiveness of Darbepoetin Alfa

Studies have shown that darbepoetin alfa can be effective in treating anemia across various conditions:

  • In chronic kidney disease patients, it can help maintain target hemoglobin levels and reduce the need for blood transfusions[4][5].
  • For cancer patients undergoing chemotherapy, it can increase hemoglobin levels and potentially improve quality of life[6].
  • In patients with myelodysplastic syndromes, it may help reduce the need for blood transfusions[7].
  • For newborns with erythroblastosis fetalis, it might help reduce the need for top-up blood transfusions[8].

Potential Side Effects

Like all medications, darbepoetin alfa can cause side effects. Some potential side effects include:

  • High blood pressure (hypertension)
  • Headache
  • Joint pain
  • Nausea
  • Swelling in the arms or legs
  • In rare cases, serious side effects like blood clots or allergic reactions can occur[6][8]

It’s important to discuss any side effects you experience with your healthcare provider.

Ongoing Research

Researchers continue to study darbepoetin alfa to understand its effects better and explore new uses. Some areas of ongoing research include:

  • Comparing different dosing schedules to find the most effective and convenient options for patients[6].
  • Investigating its use in other conditions that cause anemia.
  • Studying its long-term effects and safety profile[8].
  • Exploring its impact on quality of life for patients with various conditions[6].

As research continues, we may learn more about how to use darbepoetin alfa most effectively and safely for different patient groups.

Aspect Details
Drug Name Darbepoetin alfa (Brand name: Aranesp)
Primary Use Treatment of anemia in various medical conditions
Conditions Studied Chronic kidney disease, cancer, myelodysplastic syndromes
Administration Subcutaneous or intravenous injection
Dosing Frequency Weekly to once every 3 weeks or monthly (varies by trial)
Primary Outcomes Hemoglobin levels, red blood cell transfusion requirements
Secondary Outcomes Quality of life, safety profile, pharmacokinetics
Comparators Other anemia treatments (e.g., epoetin alfa), placebo
Safety Monitoring Blood pressure, thrombotic events, allergic reactions

FAQ

  • What is darbepoetin alfa used for in clinical trials? Darbepoetin alfa is being studied to treat anemia in patients with conditions like chronic kidney disease, cancer, and myelodysplastic syndromes. It helps stimulate red blood cell production to increase hemoglobin levels.
  • How is darbepoetin alfa administered in these trials? In the trials, darbepoetin alfa is typically given as an injection under the skin (subcutaneous) or into a vein (intravenous). The dosing schedules vary, ranging from weekly to once every 3 weeks or monthly, depending on the specific trial.
  • What are some of the potential benefits being studied? Researchers are looking at whether darbepoetin alfa can effectively increase and maintain hemoglobin levels, reduce the need for blood transfusions, improve quality of life, and potentially provide longer-lasting effects compared to other anemia treatments.
  • Are there any side effects being monitored? Yes, the trials are closely monitoring for side effects. Some potential side effects being watched for include high blood pressure, blood clots, and allergic reactions. The studies are assessing the overall safety profile of darbepoetin alfa.
  • How does darbepoetin alfa compare to other anemia treatments? Some trials are directly comparing darbepoetin alfa to other anemia medications like epoetin alfa (Procrit). They are looking at factors like effectiveness in raising hemoglobin, dosing convenience, and side effect profiles to determine potential advantages.

Ongoing Clinical Trials on Darbepoetin Alfa

  • Study of Darbepoetin Alfa to Reduce Blood Transfusion Needs During Liver Transplant Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Darbepoetin Alfa for Reducing Brain Injury in Newborns with Perinatal Arterial Ischemic Stroke

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Italy Poland Romania Slovakia

  • Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Czechia Hungary Italy Poland

Glossary

  • Anemia: A condition where you don't have enough healthy red blood cells to carry adequate oxygen to your body's tissues, often causing fatigue and weakness.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body. Hemoglobin levels are used to diagnose and monitor anemia.
  • Chronic Kidney Disease (CKD): Long-term condition where the kidneys don't work as well as they should, often leading to anemia.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells, often resulting in anemia.
  • Erythropoiesis: The process of producing red blood cells in the body.
  • Subcutaneous: Beneath the skin. Refers to injections given into the fatty tissue just under the skin.
  • Intravenous: Into a vein. Refers to medications given directly into the bloodstream through a vein.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to carry out daily activities, often assessed in clinical trials.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.

References

  1. https://clinicaltrials.gov/study/NCT02506881
  2. https://clinicaltrials.gov/study/NCT02506868
  3. https://clinicaltrials.gov/study/NCT00386152
  4. https://clinicaltrials.gov/study/NCT00096915
  5. https://clinicaltrials.gov/study/NCT00369733
  6. https://clinicaltrials.gov/study/NCT00540696
  7. https://clinicaltrials.gov/study/NCT00230321
  8. https://clinicaltrials.gov/study/NCT03104426